William Blair Expects Reduced Earnings for Sera Prognostics

Sera Prognostics, Inc. (NASDAQ:SERA) – Equities researchers at William Blair dropped their Q3 2025 earnings per share estimates for Sera Prognostics in a report released on Monday, February 3rd. William Blair analyst A. Brackmann now forecasts that the company will post earnings per share of ($0.24) for the quarter, down from their prior estimate of ($0.23). The consensus estimate for Sera Prognostics’ current full-year earnings is ($0.96) per share. William Blair also issued estimates for Sera Prognostics’ Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($0.98) EPS.

Sera Prognostics (NASDAQ:SERA) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.09 million. During the same period last year, the business earned ($0.23) earnings per share.

Sera Prognostics Stock Down 5.9 %

Shares of NASDAQ SERA opened at $4.96 on Wednesday. The business has a 50-day moving average of $7.31 and a two-hundred day moving average of $7.31. Sera Prognostics has a 1 year low of $4.61 and a 1 year high of $12.35.

Institutional Trading of Sera Prognostics

Several institutional investors and hedge funds have recently made changes to their positions in SERA. Barclays PLC increased its position in Sera Prognostics by 321.6% in the 3rd quarter. Barclays PLC now owns 39,450 shares of the company’s stock valued at $308,000 after acquiring an additional 30,093 shares during the period. JPMorgan Chase & Co. increased its position in Sera Prognostics by 7,357.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company’s stock valued at $6,902,000 after acquiring an additional 873,002 shares during the period. Geode Capital Management LLC increased its position in Sera Prognostics by 8.9% in the 3rd quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock valued at $4,578,000 after acquiring an additional 47,969 shares during the period. Quest Partners LLC increased its position in Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock valued at $50,000 after acquiring an additional 5,415 shares during the period. Finally, Sanders Morris Harris LLC increased its position in Sera Prognostics by 165.7% in the 4th quarter. Sanders Morris Harris LLC now owns 90,600 shares of the company’s stock valued at $725,000 after acquiring an additional 56,500 shares during the period. 54.64% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Joshua Phillips sold 12,163 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $6.39, for a total value of $77,721.57. Following the completion of the sale, the director now directly owns 2 shares of the company’s stock, valued at approximately $12.78. The trade was a 99.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Austin Aerts sold 7,179 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $7.32, for a total value of $52,550.28. Following the completion of the sale, the chief financial officer now directly owns 291,486 shares of the company’s stock, valued at $2,133,677.52. The trade was a 2.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 93,215 shares of company stock valued at $666,835 in the last ninety days. Insiders own 15.80% of the company’s stock.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.